Exprimental research on K-ras mutation and the resistance to cetuximab

WU Jun,JI Jun,ZHANG Jun,MA Tao,YE Zheng-bao,LIU Bing-ya,ZHU Zheng-gang

2009-01-01

Abstract:Objective To investigate the possible mechanism of K-ras mutation induced resistance to cetuximab. Methods Two colon cancer cell lines, HT29 and SW620, which were epidermal growth factor receptor (EGFR) positive, but separately with K-ras wild type and mutant type, were screened. The cytotoxic effect and apoptosis-inducing effect of cetuximab in vitro were evaluated via the cell proliferation assay (CCK8) and flow cytometry (Annexin V labeled). Subcutaneous xenograft nude mice model was established, and divided into 4 groups:HT29-C225, HT29-NS, SW620-C225 and SW620-NS; the inhibitory effects of cetuximab on these 2 colon cancer cell lines in vivo were observed. The EGFR expression, K-ras status, its down-stream signal protein AKT and its phospho-protein in EGFR pathway were detected by immunohistochemical staining and Western-blot. Results To colon cancer xenograft models, cetuximab significantly inhibited the growth of colon cancer xenograft with the K-ras wild-type; yet, in colon cancer xenograft with the K-ras mutant-type, cetuximab did not inhibit the tumor growth. Detailed molecular detection demonstrated that the expression of phospho-AKT was elevated in the K-ras mutant colon cancer xenograft. Conclusions The K-ras status might influence the effects of cetuximab treatment. K-rass mutation might lead to the spontaneous activation of its downstream signal adaptor protein AKT, thus in turn trigger the EGFR pathway activation and cause cetuximab resistance.